Literature DB >> 16330455

The relationship between proliferation and apoptosis in patients with monoclonal gammopathy of undetermined significance or multiple myeloma.

Vlastimil Scudla, Marta Ordeltova, Jaroslav Bacovsky, Marketa Vytrasova, Pavel Horak, Jiri Minarik.   

Abstract

Multiple myeloma (MM) is a clonal neoplastic lymphoproliferative disease affecting terminally differentiated B cells i.e. plasma cells characterized by slow proliferation activity and different resistance to apoptosis with latent accumulation of myeloma cells in the bone marrow. This process is induced by failure of normal tissue homeostatic mechanisms. We compared plasma cell proliferation and apoptic indices in various phases of MM and in monoclonal gammophaty of untetermined significance.

Entities:  

Mesh:

Year:  2005        PMID: 16330455

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  4 in total

1.  Proliferation to Apoptosis Tumor Cell Ratio as a Biomarker to Improve Clinical Management of Pre-Malignant and Symptomatic Plasma Cell Neoplasms.

Authors:  María A Vasco-Mogorrón; José A Campillo; Adela Periago; Valentin Cabañas; Mercedes Berenguer; María C García-Garay; Lourdes Gimeno; María F Soto-Ramírez; María D Martínez-Hernández; Manuel Muro; Alfredo Minguela
Journal:  Int J Mol Sci       Date:  2021-04-09       Impact factor: 5.923

2.  Expression profile of telomere-associated genes in multiple myeloma.

Authors:  Rafael Díaz de la Guardia; Purificación Catalina; Julieta Panero; Carolina Elosua; Andrés Pulgarin; María Belén López; Verónica Ayllón; Gertrudis Ligero; Irma Slavutsky; Paola E Leone
Journal:  J Cell Mol Med       Date:  2012-12       Impact factor: 5.310

3.  Stathmin 1 expression in plasma cell neoplasms.

Authors:  João Agostinho Machado-Neto; Fernando Vieira Pericole; Fernando Ferreira Costa; Fabiola Traina; Sara Teresinha Olalla Saad
Journal:  Rev Bras Hematol Hemoter       Date:  2017-03-11

4.  TC2N, a novel oncogene, accelerates tumor progression by suppressing p53 signaling pathway in lung cancer.

Authors:  Xiang-Lin Hao; Fei Han; Ning Zhang; Hong-Qiang Chen; Xiao Jiang; Li Yin; Wen-Bin Liu; Dan-Dan Wang; Jian-Ping Chen; Zhi-Hong Cui; Lin Ao; Jia Cao; Jin-Yi Liu
Journal:  Cell Death Differ       Date:  2018-09-25       Impact factor: 15.828

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.